Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica J Duncan

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Comprehensive Psychiatry|March 15, 2021
Polygenic risk scores differentiate schizophrenia patients with toxoplasma gondii compared to toxoplasma seronegative patientsAdriana Lori, Dimitrios Avramopoulos, Alex W Wang, et al.
Psychopharmacology|March 13, 2003
Effect of treatment status on prepulse inhibition of acoustic startle in schizophreniaErica J Duncan, Sandor Szilagyi, Toby R Efferen, et al.
Frontiers in Behavioral Neuroscience|November 30, 2011
Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fearSeth D Norrholm, Kemp M Anderson, Ilana W Olin, et al.
Schizophrenia Research|October 12, 2004
Effects of D-cycloserine on negative symptoms in schizophreniaErica J Duncan, Sandor Szilagyi, Marion P Schwartz, et al.
Psychophysiology|February 27, 2019
Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patientsTanja Jovanovic, Erica J Duncan, Joanna Kaye, et al.
Journal of Clinical Psychopharmacology|February 15, 2021
Effects of Oxytocin on Emotion Recognition in Schizophrenia: A Randomized Double-Blind Pilot StudyElissar Andari, Nicholas M Massa, Molly D Fargotstein, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Comprehensive Psychiatry|March 15, 2021
Polygenic risk scores differentiate schizophrenia patients with toxoplasma gondii compared to toxoplasma seronegative patientsAdriana Lori, Dimitrios Avramopoulos, Alex W Wang, et al.
Psychopharmacology|March 13, 2003
Effect of treatment status on prepulse inhibition of acoustic startle in schizophreniaErica J Duncan, Sandor Szilagyi, Toby R Efferen, et al.
Frontiers in Behavioral Neuroscience|November 30, 2011
Versatility of fear-potentiated startle paradigms for assessing human conditioned fear extinction and return of fearSeth D Norrholm, Kemp M Anderson, Ilana W Olin, et al.
Schizophrenia Research|October 12, 2004
Effects of D-cycloserine on negative symptoms in schizophreniaErica J Duncan, Sandor Szilagyi, Marion P Schwartz, et al.
Psychophysiology|February 27, 2019
Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patientsTanja Jovanovic, Erica J Duncan, Joanna Kaye, et al.
Journal of Clinical Psychopharmacology|February 15, 2021
Effects of Oxytocin on Emotion Recognition in Schizophrenia: A Randomized Double-Blind Pilot StudyElissar Andari, Nicholas M Massa, Molly D Fargotstein, et al.
Pageof 3